Further research on Phytofare and diabetes

Upcoming clinical trial by Plandaí Biotechnology to offer more information on effectiveness of Phytofare as a treatment

Plandaí Biotechnology will conduct a human clinical trial to study the effectiveness of using its highly bioavailable green tea extract, Phytofare Catechin Complex, to regulate blood glucose levels in type 2 diabetics.

This follows previous positive data recently published in the Journal of Human Nutrition and Dietetics, showing success with a green tea supplement that contained one of the tea plant's eight catechins.

Phytofare contains all eight of the catechins found in the tea plant. Therefore, this upcoming research using Phytofare extract is expected to produce improved results.

Catechins

Catechins are known as antioxidants, which protect the body from free radicals, thought to play a role in heart disease and cancer. Catechins are found in the greatest abundance in the leaves of the tea plant.

Plandaí's product has proven in human clinical trials that it can deliver 10 times more of the catechins into the bloodstream and keep antioxidants at therapeutic levels for more than 24 hours.

Previous research

In the earlier clinical trial, more than 400 pregnant women diagnosed with gestational diabetes mellitus (GDM) participated in investigating the effects of the catechin epigallocatechin 3-gallate (EGCG), in terms of both maternal and neonatal treatment outcomes.

Data suggests that mothers with GDM who were given EGCG as a supplement during the third trimester of their pregnancy had significantly improved maternal diabetic parameters and fewer cases of neonatal complications, compared to similar women given a placebo supplement.

Upcoming trial

During Plandaí's clinical trial, participants will be given Phytofare, which will deliver all eight catechins into the bloodstream of each participant in the study.

Other advantages is that the bioavailable extract can be further advanced by entrapping it in liposomes.

Positive data from Plandaí's upcoming clinical trial in type 2 diabetes highlight the product as a viable solution for treatment and management of type 2 diabetes worldwide.

Companies